Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN has received additional FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay on DiaSorin's LIAISON® XS platform. This expands access to automated TB testing solutions across diverse healthcare settings, from small clinics to large hospitals. The QuantiFERON test, a leading interferon-gamma release assay (IGRA), enhances patient care by replacing outdated tuberculin skin tests. The partnership with DiaSorin enhances the ability to meet the rising demand for TB detection, which affects around one-third of the global population.
QIAGEN N.V. (NYSE: QGEN) confirmed that its PCR tests remain effective in detecting SARS-CoV-2 infections amid the emergence of the B.1.1.529 variant from South Africa. The efficacy was validated through data from GISAID and GenBank. QIAGEN’s tests include the artus SARS-CoV-2 Prep&AMp;Amp UM Kit, QIAstat-Dx systems, and NeuMoDx PCR systems, all confirming reliable results against the new variant. The company will continue biweekly surveillance on its tests' performance to adapt to further viral mutations.
QIAGEN N.V. (NYSE: QGEN) has joined the "Business Ambition for 1.5˚C" campaign, committing to achieve net-zero carbon emissions by 2050. The company aims for a minimum of 40% reduction in Scope 1 and 2 emissions, and 10% in Scope 3 emissions by 2030 from a 2020 baseline. This initiative aligns with the Paris Climate Agreement and positions QIAGEN among over 2,000 global entities in the Race to Zero Campaign. QIAGEN is embedding environmental sustainability into operations, including using renewable energy and reducing packaging plastics.
QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of
QIAGEN N.V. reported an 11% increase in Q3 2021 net sales, reaching
QIAGEN announced the CE-marking and upcoming launch of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test. This test differentiates between influenza A, B, RSV, and SARS-CoV-2, crucial for flu season diagnoses. It enhances QIAGEN's extensive portfolio of PCR solutions combatting COVID-19, delivering results in about an hour without sample preparation. The product's introduction responds to the urgent need for accurate diagnostics highlighted by the pandemic, facilitating informed therapeutic decisions and optimizing patient management.
QIAGEN has completed its relocation to the CityLabs 2.0 facility in Manchester, establishing it as a global hub for diagnostics development and Precision Medicine. This expansion supports the company's role in co-developing companion diagnostics with pharmaceutical partners. The site employs around 300 staff and will enhance hybrid and remote work options. QIAGEN has numerous FDA-approved companion diagnostic indications and collaborations with over 25 pharmaceutical firms, reinforcing its commitment to advancing Precision Medicine.
QIAGEN N.V. (NYSE: QGEN) has announced the release of its third quarter and year-to-date results scheduled for November 3, 2021. The report will be available at approximately 21:05 CET / 16:05 EDT. Following this, a conference call will occur on November 4 at 14:30 Frankfurt time where CEO Thierry Bernard and CFO Roland Sackers will discuss the results. Interested parties can access the call via multiple phone numbers, and a replay will be made available after the event.
QIAGEN has launched the QIAreach QuantiFERON-TB test, receiving CE marking to enhance global tuberculosis (TB) detection, particularly in high burden and low-resource areas. This portable device utilizes proven QuantiFERON technology to ensure reliable TB infection testing without needing extensive lab infrastructure. Clinical evaluations show high sensitivity compared to existing standards. Collaborations with distribution partners aim to facilitate affordable access across low and middle-income countries, contributing to global TB elimination targets.
QIAGEN N.V. (NYSE: QGEN) has received a $3.4 million U.S. government contract to enhance production for its NeuMoDx PCR testing systems, supporting ongoing COVID-19 testing efforts. The company aims to increase its output to over 16 million tests per year by March 2022, up from approximately 10 million. This follows a previous $600,000 contract to boost reagent production. The contracts emphasize the critical role of PCR testing in managing the pandemic and underline QIAGEN's commitment to providing essential diagnostic solutions.